Value-Based Contracts: Medicaid Best Price Concerns Could Be Eased With CMS Guidance
Absent any legislative remedy, an administrative fix could provide manufacturers with confidence that value-based arrangements won’t trigger a new best price, Duke Margolis policy experts propose.
You may also be interested in...
House Republicans are eager to keep working on legislation to permit innovative payment models for curative gene and cell therapies. Democrats, for now, are focused on other priorities.
Centers for Medicare & Medicaid Innovation could enable outcomes-based contracting for novel, 'curative' therapies follow something like the FDA’s Accelerated Approval model, former top HHS official suggests.
Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.